Possible influence of opioid normetabolites on the onset, magnitude and quality of the opioid abstinence syndrome.
D000284:Administration, Oral; D000818:Animals; D001711:Biotransformation; D001835:Body Weight / Q000187:drug effects; D003061:Codeine / Q000378:metabolism; D003640:Dealkylation; D011431:Dextropropoxyphene / Q000378:metabolism; D004285:Dogs; D006168:Guinea Pigs; D006801:Humans; D007279:Injections, Subcutaneous; D007981:Levorphanol / Q000378:metabolism; D008614:Meperidine / Q000378:metabolism; D008692:Methadyl Acetate / Q000378:metabolism; D009020:Morphine / Q000378:metabolism; D009294:Narcotics / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D019966:Substance-Related Disorders / Q000209:etiology; D013997:Time Factors
D009294:Narcotics; D007981:Levorphanol; D009020:Morphine; D008614:Meperidine; D008692:Methadyl Acetate; D011431:Dextropropoxyphene; D003061:Codeine